A paper just published in Nature bolsters that view. It provides a big dollop of evidence in support of an emerging idea that artificial sweeteners are not directly bad for people (humans cannot even digest most of them). Rather, they may be bad for the zillions of microbes that live in people’s guts—and this, in […]
Patients who use insulin pumps rather than daily insulin injections have a 29 percent reduced risk in mortality and a 43 percent reduced risk of fatal heart disease, a new study reports.
Like something straight out of HBO’s series Silicon Valley, former Allscripts CEO Glen Tullman made a splash on the TechCrunch Disrupt stage last week introducing the latest and greatest in cloud-based glucose testing tech: Livongo, with its new In Touch meter, backed by a $10 million seed investment.
This week, Wil hears a heart-breaking story about a very scary hypo and how it’s making one family wonder what options exist that could help… perhaps some diabetes tech that could be worn on the wrist? In these times of #WeAreNotWaiting, Wil has many thoughts to share on the possibilities…
The sensor records blood glucose levels every minute, sampling the interstitial fluid using a 5mm long and .4 mm wide filament that penetrates the skin. It doesn’t require any finger prick calibration, unlike all other currently available continuous glucose monitors.
Eli Lilly and Company’s basal insulin peglispro (BIL) demonstrated a statistically significant lower hemoglobin A1c (HbA1c) compared with insulin glargine (Lantus®) at 26 weeks and 52 weeks, respectively, in the IMAGINE-1 and IMAGINE-3 Phase III clinical trials in patients with type 1 diabetes. Patients in these trials were also taking mealtime insulin.
Princeton researcher Claire Gmachl has announced that her laser glucose monitor meets FDA requirements for accuracy, putting it on par with monitor devices now on the market.
If you have Type 1 diabetes and are out of the “honeymoon period,” you’ve probably been told that your pancreas has stopped producing insulin. But it turns out that information may be wrong. Many people with Type 1 still produce at least some insulin, even years after diagnosis.
This article brings an extensive summary of all the diabetes technology highlights for August 2014.
Afrezza®, a dry-powder formulation of recombinant human regular insulin, was recently approved by the US Food and Drug Administration.[1] Afrezza is indicated for use in adults ≥ 18 years of age with type 1 or type 2 diabetes mellitus (T1DM or T2DM); however, in those with T1DM, Afrezza must be used in combination with long-acting […]
An international team of researchers conducted a trial as part of the multinational EDITION 1 study, comparing the efficacy and safety of new insulin glargine 300 units/mL (Gla-300) with glargine 100 units/mL (Gla-100) in people with type 2 diabetes on basal insulin (≥42 units/day) plus mealtime insulin.
Unfortunately, Medicare policy hasn’t kept up with evolving diabetes technology, and policymakers have left out CGMs from the list of reimbursable diabetes devices. CGMs have fallen into the dreaded Medicare limbo of new devices, according to a recent blogpost from Senator Susan Collins (R-Maine).
Scientists from the American Diabetes Association (ADA) held an open Twitter chat to discuss new guidelines for children with Type 1 diabetes, as part of the rollout of the association’s first Type 1-only position paper. Endocrinologists Dr. Jane Chiang and Dr. Sue Kirkman fielded questions for the ADA.
All Dr. Christopher Jacobs’ friend wanted a lancing device that didn’t cause pain. And after hearing the longtime type 1 diabetic lament the discomfort he felt from the many finger pricks required to test his blood glucose levels, Jacobs was intrigued by the challenge.
The researchers have developed a prototype laser-based system to allow sufferers of diabetes to check their blood sugar levels without using a needle stick to draw blood. The system works by directing a laser beam at the patient’s palm and measuring the amount of absorption and scattering when the laser interacts with dermal interstitial fluid, […]
One of the basic premises of wearing an insulin pump is flawed, at least in my experience. And that’s the promise that a pump somehow reduces the presence of diabetes in your life, or transforms it into a mere inconvenience.
The FreeStyle Libre has a small sensor around an inch in diameter that can be stuck onto the skin, such as onto the back of your upper arm. Readings are taken by swiping the reader over the patch. Readings can be taken as often as you like and will automatically take glucose readings once every […]
The U.S. Food and Drug Administration (FDA) today granted tentative approval for Basaglar(TM) (insulin glargine injection), which is indicated to improve glycemic control in adults with type 2 diabetes and in combination with mealtime insulin in adults and pediatric patients with type 1 diabetes.
For patients with impaired glucose tolerance or early diabetes, use of insulin glargine (Lantus) was the best predictor of maintaining a lower hemoglobin A1c (HbA1c) level over 5 years, according to a subanalysis of the ORIGIN trial.
With regular sugar taking a nutritional beating and artificial sweeteners unable to shake their sketchy made-in-the-lab connotations, it’s no wonder newcomers like stevia and agave are conquering our morning coffee (and the world of packaged foods).